Analysis of immunological status using CFSE-MLR for de-novo kidney transplant recipients who are treated with Everolimus commencing 3 months after surgery.

Analysis of immunological status using CFSE-MLR for de-novo kidney transplant recipients who are treated with Everolimus commencing 3 months after surgery. - Analysis of immunological status using CFSE-MLR for kidney transplant recipients treated with Everolimus.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010743

Enrollment

Registered

2013-05-16

Start date

2013-05-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

After kidney transplantation

Interventions

Reduced Cyclosporine plus Everolimus treatment Normal dose Cyclosporine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: de-novo kidney transplant recipients

Exclusion criteria

Exclusion criteria: rejection severe proteinuria

Design outcomes

Primary

Measure	Time frame
Comparison of CFSE-MLR categorization between reduced Cyclosporine plus Everolimus group and normal dose Cyclosporine group.	—

Countries

Japan

Contacts

Public ContactKentaro Ide

Hiroshima University Hospital Trasnplantation surgery

ideken@hiroshima-u.ac.jp082-257-5222

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026